Literature DB >> 14758132

Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer.

Juan J González-Aguilera1, Soledad Oliart, Mariano Moreno Azcoita, Antonia M Fernández-Peralta.   

Abstract

Despite the fact that the mutations in K-ras codon 12 and TP53 are common abnormalities in colorectal cancer, the determination of K-ras mutation combined with TP53 gene mutation, with diagnostic and prognostic purposes is still controversial. We have analyzed K-ras and TP53 mutations in 77 sporadic colorectal adenocarcinomas by means of polymerase chain reaction and sequencing. We observed a negative correlation between both K-ras and TP53 mutations. Patients with mutations in K-ras but not in TP53 exhibited worse survival rates than those with mutations in TP53 and not in K-ras. Moreover, we found the worst outcome in patients with mutations in both K-ras and TP53. These results may relate to the previously published data about primary human and rodent cells, in which transformation by Ras require either a cooperating oncogene or the inactivation of tumor suppressors such as p53 or p16. In conclusion, simultaneous mutations in K-ras and TP53 are indicative of a worse prognosis in sporadic colorectal cancer.

Entities:  

Mesh:

Year:  2004        PMID: 14758132     DOI: 10.1097/01.coc.0000045920.49210.7a

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  11 in total

1.  Prognosis and clinical characteristics of colorectal cancer patients with KRAS gene mutation: a 5-year follow-up study.

Authors:  Dongyang Yang; Xiaorong Lai; Fei Xu; Ying Li; Weiwei Jiang; Dong Ma
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

Review 2.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

3.  Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.

Authors:  Antonia M Fernández-Peralta; Lydia Daimiel; Nargisse Nejda; Daniel Iglesias; Vicente Medina Arana; Juan J González-Aguilera
Journal:  Int J Colorectal Dis       Date:  2009-08-11       Impact factor: 2.571

4.  Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma.

Authors:  Dan-ping Zhao; Xiao-wen Ding; Jia-ping Peng; Yi-xiong Zheng; Su-zhan Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2005-12       Impact factor: 3.066

5.  Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis.

Authors:  Javier Garde Noguera; Eloisa Jantus-Lewintre; Mireia Gil-Raga; Elena Evgenyeva; Sonia Maciá Escalante; Antonio Llombart-Cussac; Carlos Camps Herrero
Journal:  Mol Clin Oncol       Date:  2017-02-03

6.  The BRAF mutation is associated with the prognosis in colorectal cancer.

Authors:  Tae Sung Ahn; Dongjun Jeong; Myoung Won Son; Haeil Jung; Soyoung Park; Hyungjoo Kim; Sang Byung Bae; Han Jo Kim; Young-Woo Jeon; Moon Soo Lee; Moo-Jun Baek
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-19       Impact factor: 4.553

7.  Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer.

Authors:  E Miranda; A Destro; A Malesci; E Balladore; P Bianchi; E Baryshnikova; G Franchi; E Morenghi; L Laghi; L Gennari; M Roncalli
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640

8.  Biomarkers in precision therapy in colorectal cancer.

Authors:  Marlies S Reimers; Eliane C M Zeestraten; Peter J K Kuppen; Gerrit Jan Liefers; Cornelis J H van de Velde
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-08-23

9.  Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.

Authors:  Eduardo Díaz-Rubio; Auxiliadora Gómez-España; Bartomeu Massutí; Javier Sastre; Margarita Reboredo; José Luis Manzano; Fernando Rivera; M José Safont; Clara Montagut; Encarnación González; Manuel Benavides; Eugenio Marcuello; Andrés Cervantes; Purificación Martínez de Prado; Carlos Fernández-Martos; Antonio Arrivi; Inmaculada Bando; Enrique Aranda
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240

10.  Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy.

Authors:  Seung Tae Kim; Kyong Hwa Park; Jun Suk Kim; Sang Won Shin; Yeul Hong Kim
Journal:  Cancer Res Treat       Date:  2013-03-31       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.